MPIP co-sponsors collaborated with journal editors to develop best practice recommendations to improve reporting of drug adverse events in industry-sponsored clinical trial publications.
New look for MPIP website to feature new resources and enhance the user experience.
A recent MPIP survey benchmarked journal editor perceptions regarding change in transparency and credibility of industry-sponsored clinical trial publications in the past 5 years.
Enter your email address below and select "Sign me up" to receive updates on MPIP initiatives.
Recommendations to Improve Adverse Event Reporting in Clinical Trial Publications: A Joint Pharmaceutical Industry/Journal Editor Perspective, published in The BMJ in October 2016, provides guidance on clinically relevant and more informative adverse event reporting, to improve patient care and increase the credibility of industry-sponsored publications.
Medical Publishing Insights & Practices (MPIP) was founded in 2008 by members of the pharmaceutical industry and the International Society for Medical Publication Professionals (ISMPP) to elevate trust, transparency, and integrity in reporting the results of industry-sponsored research. The major goal of MPIP is to encourage more effective partnership between trial sponsors and medical journals to raise standards in medical publications and expand access to research results.